1172612-46-2

Basic information

• Product Name: 2-methylsulfanyl-5-phenylethynyl-pyrimidine
• Synonyms: 2-methylsulfanyl-5-phenylethynyl-pyrimidine
• CAS NO: 1172612-46-2
• Molecular Weight: 226.302
• Mol File: 1172612-46-2.mol

Chemical Properties

• CAS DataBase Reference: 2-methylsulfanyl-5-phenylethynyl-pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methylsulfanyl-5-phenylethynyl-pyrimidine(1172612-46-2)
• EPA Substance Registry System: 2-methylsulfanyl-5-phenylethynyl-pyrimidine(1172612-46-2)

Safety Data

• Hazardous Substances Data: 1172612-46-2(Hazardous Substances Data)

Upstream product

• 14001-67-3 5-bromo-2-methylthiopyrimidine 
• 536-74-3 phenylacetylene 

Downstream Products

• 1172612-43-9 methyl-(5-phenylethynyl-pyrimidin-2-yl)-amine 
• 1295501-54-0 cyclopentyl-(5-phenylethynyl-pyrimidin-2-yl)-amine 

Relevant articles and documents

ETHYNYL DERIVATIVES

The present invention relates to ethynyl derivatives of formula I wherein U, V, W, Y, R, R1, R2, R3 and R3′ are as described herein. It has been found that the compounds of general formula I are allosteric modul

ETHYNYL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

The present invention relates to ethynyl derivatives of formula I wherein Y is N or CH; with the proviso that Y can only be CH, if at least on of U, V or W are N; U is N or C-R4; V and W are independently N or CH; with the proviso that only one

POSITIVE ALLOSTERIC MODULATORS (PAM)

The present invention relates to phenylethynyl compounds of formula I wherein R1, R2, X, L, R3, R4, R4′, cyc, and n are as defined in the specification and claims and to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5). They are useful for the treatment of schizophrenia or cognitive diseases.

POSITIVE ALLOSTERIC MODULATORS (PAM)

The present invention relates to phenylethynyl derivatives of formula (I) wherein R1 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen; R2 is hydrogen, lower alkyl, =O, lower alkoxy, phenyl, hydroxy or lower alkyl substituted by hydroxy; X is N, CF or CH; L is -NR3-, -NHC(R3)2-, -O-, -OC(R3)2-, -CR4R4'-; R3 is hydrogen or lower alkyl; R4/R4' are independently from each other hydrogen or lower alkyl; cyc is cycloalkyl or heterocycloalkyl, or is a non-aromatic bicycle selected from 7-oxa- bicyclo[2.2.1]hept-1-yl or bicyclo[2.2.1]hept-1-yl; n is 1, 2 or 3; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. It has now surprisingly been found that the compounds of general formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5). They are useful for the treatment of schizophrenia or cognitive diseases.

Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl) pyrimidines

We describe the synthesis and SAR of a series of analogues of the mGlu5 partial antagonist 5-(phenylethynyl)pyrimidine. New molecular switches are identified that modulate the pharmacological activity of the lead compound. Slight structural modifications